Nana Wilberforce

Jan 23, 2025 | wilmerhale.com | Nana Wilberforce |Lauren Ige |Esperanza Gilbert |John W. O'Toole

The incoming Trump administration will bring in new antitrust leadership with new priorities.

Mar 25, 2024 | wilmerhale.com | Leon Greenfield |Nana Wilberforce |Perry A. Lange |Hartmut Schneider |Dominic Vote |Jonathan R. Wright | +2 more

The healthcare industry remains a focal point of President Biden’s antitrust agenda. The President’s July 2021 Executive Order on Promoting Competition in the American Economy called on federal agencies to focus antitrust enforcement efforts on health care, among other industries, and to coordinate on oversight, investigations, and remedies where agency jurisdiction overlaps. The Federal Trade Commission (FTC), the Department of Justice Antitrust Division (DOJ), and the Department of Health and Human Services (HHS) later announced plans to address antitrust concerns in the healthcare industry. FTC Chair Lina M. Khan highlighted ongoing healthcare-related enforcement initiatives in a February 2024 speech before the American Medical Association. The FTC, DOJ, and HHS launched an interagency inquiry into private equity and corporate ownership in health care shortly thereafter. In this client alert, we summarize the latest federal antitrust activities in the healthcare industry.